Botanix Pharmaceuticals (ASX:BOT) EBITDA Margin %: -184.20% (As of Dec. 2025)

What is Botanix Pharmaceuticals EBITDA Margin %?

Botanix Pharmaceuticals ASX:BOT -5.00% EBITDA Margin % is -184.20% as of Dec. 2025. The stock has 7 warning signs investors should review. Among 945 Biotechnology companies, Botanix Pharmaceuticals ranks worse than 68.78% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Botanix Pharmaceuticals's EBITDA for the six months ended in Dec. 2025 was A$-30.40 Mil. Botanix Pharmaceuticals's Revenue for the six months ended in Dec. 2025 was A$16.51 Mil. Therefore, Botanix Pharmaceuticals's EBITDA margin for the quarter that ended in Dec. 2025 was -184.20%.

Botanix Pharmaceuticals (ASX:BOT) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Botanix Pharmaceuticals EBITDA Margin % Related Terms

Botanix Pharmaceuticals EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Botanix Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Botanix Pharmaceuticals EBITDA Margin % Chart

Botanix Pharmaceuticals Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

EBITDA Margin %

Get a 7-Day Free Trial

0.00

-8,700.97

-2,290.03

-1,427.17

Botanix Pharmaceuticals Semi-Annual Data
	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24	Jun25	Dec25
EBITDA Margin %	Get a 7-Day Free Trial															-1,442.33	-3,720.54	-8,594.22	-968.70	-184.20

ASX:BOT vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Botanix Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Botanix Pharmaceuticals EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Botanix Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Botanix Pharmaceuticals's EBITDA Margin % falls into.

Save Embed

Botanix Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Botanix Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Jun. 2025 is calculated as

EBITDA Margin %	=	EBITDA (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	-82.162	/	5.757
	=	-1,427.17 %

Botanix Pharmaceuticals's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %	=	EBITDA (Q: Dec. 2025 )	/	Revenue (Q: Dec. 2025 )
	=	-30.404	/	16.506
	=	-184.20 %

Frequently Asked Questions Learn more about EBITDA Margin % →

What does a EBITDA Margin % of -184.20% mean?

Botanix Pharmaceuticals (ASX:BOT) has a EBITDA Margin % of -184.20% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Botanix Pharmaceuticals and its competitors. According to the industry distribution chart, Botanix Pharmaceuticals ranks #650 out of 945 companies in the Biotechnology industry, placing it in the top 68.8%.

Is Botanix Pharmaceuticals' EBITDA Margin % too high?

Botanix Pharmaceuticals' current EBITDA Margin % is -184.20%. Based on the distribution chart, Botanix Pharmaceuticals ranks #650 out of 945 companies in the Biotechnology industry, which is below the industry midpoint.

How does Botanix Pharmaceuticals' EBITDA Margin % compare to VRTX and REGN?

According to the Biotechnology industry distribution chart, Botanix Pharmaceuticals ranks #650 out of 945 companies for EBITDA Margin %. This places Botanix Pharmaceuticals in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBITDA Margin % for a Biotechnology company?

A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBITDA Margin % mean?

A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Botanix Pharmaceuticals and its competitors. Botanix Pharmaceuticals's current EBITDA Margin % is -184.20%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Botanix Pharmaceuticals stock overvalued right now?

Botanix Pharmaceuticals (ASX:BOT) has a current EBITDA Margin % of -184.20%. The current EBITDA Margin % is -184.20%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBITDA Margin % calculated?

EBITDA Margin % is calculated from a company's financial statements. For Botanix Pharmaceuticals (ASX:BOT), the current EBITDA Margin % is -184.20% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Botanix Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:LTP ASX:CYP ASX:ATX ASX:ENP ASX:IMM ASX:NXN ASX:PTX ASX:IMU ASX:RAD ASX:NUZ VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges BXPHF:USA

Address 41 - 47 Colin Street, Suite 3, West Perth, WA, AUS, 6005

Website https://www.botanixpharma.com

Botanix Pharmaceuticals Ltd is a dermatology company. The company focuses on developing safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system for all skin diseases. The company's product pipeline includes BTX 1503 - Moderate to Severe Acne, BTX 1204 - Atopic Dermatitis, BTX 1702 - Rosacea, Sofdra - Axillary Hyperhidrosis, and others. The majority of Revenue is derived from Australia.